308 related articles for article (PubMed ID: 11022892)
1. Kidney angiotensin receptors and their role in renal pathophysiology.
Sandberg K; Ji H
Semin Nephrol; 2000 Sep; 20(5):402-16. PubMed ID: 11022892
[TBL] [Abstract][Full Text] [Related]
2. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
Carnovali M
Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
[TBL] [Abstract][Full Text] [Related]
3. [Are the antagonists of angiotensin II AT1 receptors protectors of the kidney?].
Deray G
Arch Mal Coeur Vaiss; 1999 Jul; 92(7):903-7. PubMed ID: 10443311
[TBL] [Abstract][Full Text] [Related]
4. [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure].
Sandmann S; Unger T
Drugs; 2002; 62 Spec No 1():43-52. PubMed ID: 12036388
[TBL] [Abstract][Full Text] [Related]
5. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
Brewster UC; Perazella MA
Am J Med; 2004 Feb; 116(4):263-72. PubMed ID: 14969655
[TBL] [Abstract][Full Text] [Related]
6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
7. Impact of renin-angiotensin system blockade on structure and function of glomerular membrane components in animal models of kidney disease.
Remuzzi A; Mohamed EI
Exp Nephrol; 1996; 4 Suppl 1():27-33. PubMed ID: 9001894
[TBL] [Abstract][Full Text] [Related]
8. The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease.
Raij L
Am J Hypertens; 2005 Apr; 18(4 Pt 2):95S-99S. PubMed ID: 15837551
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
Cantarovich F; Rangoonwala B
Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
[TBL] [Abstract][Full Text] [Related]
10. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin receptors and development: the kidney.
Alcorn D; McCausland JE; Maric C
Clin Exp Pharmacol Physiol; 1996 Sep; 23 Suppl 3():S88-92. PubMed ID: 21143279
[TBL] [Abstract][Full Text] [Related]
12. The renin-angiotensin system: importance in physiology and pathology.
Ferrario CM
J Cardiovasc Pharmacol; 1990; 15 Suppl 3():S1-5. PubMed ID: 1691411
[TBL] [Abstract][Full Text] [Related]
13. Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade.
Navar LG; Harrison-Bernard LM; Imig JD; Wang CT; Cervenka L; Mitchell KD
J Am Soc Nephrol; 1999 Apr; 10 Suppl 12():S266-72. PubMed ID: 10201881
[TBL] [Abstract][Full Text] [Related]
14. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibition in renal and hypertensive disorders.
Götz R; Heidbreder E; Heidland A
Clin Physiol Biochem; 1990; 8 Suppl 1():25-32. PubMed ID: 2257721
[TBL] [Abstract][Full Text] [Related]
16. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
Abassi Z; Armaly Z; Nakhoul F; Hoffman A
Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
[TBL] [Abstract][Full Text] [Related]
17. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension].
Burnier M
Drugs; 2002; 62 Spec No 1():21-9. PubMed ID: 12036386
[TBL] [Abstract][Full Text] [Related]
18. Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review.
Ibrahim HN; Rosenberg ME; Hostetter TH
Semin Nephrol; 1997 Sep; 17(5):431-40. PubMed ID: 9316211
[TBL] [Abstract][Full Text] [Related]
19. Renin-angiotensin blockade improves renal cGMP production via non-AT(2)-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat.
Uhlenius N; Vuolteenaho O; Tikkanen I
J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):233-9. PubMed ID: 11881129
[TBL] [Abstract][Full Text] [Related]
20. How to explain the differences between renin angiotensin system modulators.
Levy BI
Am J Hypertens; 2005 Sep; 18(9 Pt 2):134S-141S. PubMed ID: 16125050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
